Study protocol for a randomised controlled trial evaluating the effects of the orexin receptor antagonist suvorexant on sleep architecture and delirium in the intensive care unit

INTRODUCTION: Insomnia frequently occurs in patients admitted to an intensive care unit (ICU). Sleep-promoting agents may reduce rapid eye movement sleep and have deliriogenic effects. Suvorexant (Belsomra) is an orexin receptor antagonist with Food and Drug Administration (FDA) approval for the tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Azimaraghi, Omid, Hammer, Maximilian, Santer, Peter, Platzbecker, Katharina, Althoff, Friederike C, Patrocinio, Maria, Grabitz, Stephanie D, Wongtangman, Karuna, Rumyantsev, Sandra, Xu, Xinling, Schaefer, Maximilian S, Fuller, Patrick M, Subramaniam, Balachundhar, Eikermann, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Anaesthesia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371384/
https://www.ncbi.nlm.nih.gov/pubmed/32690536
http://dx.doi.org/10.1136/bmjopen-2020-038474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371384/
https://www.ncbi.nlm.nih.gov/pubmed/32690536
http://dx.doi.org/10.1136/bmjopen-2020-038474

Ejemplares similares